At the American Society of Hematology (ASH) Annual Meeting 2017, multiple abstracts will be presented highlighting clinical progress for 5 Pfizer Oncology assets. The presentations span multiple tumor types and mechanisms of action.

**Bosutinib:**

*(Abstract 900)* Second-Line Bosutinib in Patients with Chronic Phase Chronic Myeloid Leukemia (CP CML) Resistant or Intolerant to Prior Imatinib: An 8-Year Update. Brümmendorf TH. Monday, December 11. Session Type: Oral. Presentation Time: 7:30 p.m. EDT. Location: Building C, Level 2, C202-204.


*(Abstract 1618)* Bosutinib vs Imatinib for Newly Diagnosed Chronic Myeloid Leukemia in the BFORE Trial: Results by 3-Month BCR-ABL1 Transcript Level. Hochhaus A. Saturday, December 9. Session Type: Poster Session. Presentation Time: 5:30 p.m. – 7:30 p.m. EDT. Location: Building A, Level 1, Hall A2.

*(Abstract 1620)* Bosutinib in Newly Diagnosed Chronic Myeloid Leukemia (CML): Gastrointestinal and Hematological Safety Characterization in the BFORE Trial. Mauro M. Saturday, December 9. Session Type: Poster Session. Presentation Time: 5:30 p.m. – 7:30 p.m. EDT. Location: Building A, Level 1, Hall A2.

*(Abstract 2123)* Out-of-Pocket (OOP) Costs Associated with Tyrosine Kinase Inhibitors (TKIs) Used for the Treatment of US Patients (Pts) Diagnosed with Chronic Myeloid Leukemia (CML): A US Retrospective Claims Analysis. Kim R. Saturday, December 9. EDT. Session Type: Poster Session. Presentation Time: 5:30 p.m. – 7:30 p.m. EDT. Location: Building A, Level 1, Hall A2.

*(Abstract 1590)* Long-Term Cardiac, Vascular and Hypertensive Safety of Bosutinib in Patients with Philadelphia Chromosome-Positive (Ph+) Leukemia Resistant or Intolerant to Prior Therapy. Cortes JE. Saturday, December 9. Session Type: Poster Session. Presentation Time: 5:30 p.m. – 7:30 p.m. EDT. Location: Building A, Level 1, Hall A2.

*(Abstract 2899)* Optimizing Dose to Minimize Adverse Events while Maintaining Efficacy in Newly Diagnosed Chronic Myelogenous Leukemia Patients Receiving Bosutinib. Garrett M. Sunday, December 10. Session Type: Poster Session. Presentation Time: 6:00 p.m. – 8:00 p.m. EDT. Location: Building A, Level 1, Hall A2.

*(Abstract 2895)* Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: 12-Month Patient-Reported Outcomes from the BFORE Trial. Cortes J. Sunday, December 10. Session Type: Poster Session. Presentation Time: 6:00 p.m. – 8:00 p.m. EDT. Location: Building A, Level 1, Hall A2.
Gemtuzumab Ozogamicin:

(Abtract 2103) Comparative Efficacy and Safety of Gemtuzumab Ozogamicin (GO) Plus Daunorubicin-Cytarabine Combination and Comparators As Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia. Ashaye A. Saturday, December 9. Session Type: Poster Session. Presentation Time: 5:30 p.m. – 7:30 p.m. EDT. Location: Building A, Level 1, Hall A2.

(Abtract N/A) Cross-Sectional Survey of Symptoms and Health-Related Quality of Life of Adults with De Novo Acute Myeloid Leukemia (AML) in Clinical Practice. Mamolo C. Session Type: Publication Only.

Glasdegib:


(Abtract N/A) Covariate Adjusted Indirect Treatment Comparison (ITC) of Glasdegib Plus Low Dose Ara-C versus a Hypomethylating Agent for Acute Myeloid Leukemia Patients Ineligible for Intensive Chemotherapy. Tremblay G. Session Type: Publication Only.

Inotuzumab Ozogamicin:

(Abtract 886) Role of Remission Status and Prior Transplant in Optimizing Survival Outcomes Following Allogeneic Hematopoietic Stem Transplantation (HSCT) in Patients who Received Inotuzumab Ozogamicin (INO) for Relapsed / Refractory (R/R) Acute Lymphoblastic Leukemia (ALL). Kebriaei P. Monday, December 11. Session Type: Oral. 7:00 p.m. EDT. Location: Building C, Level 3, Georgia BR 1-3.

(Abtract 1271) Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the Global Phase 3 INO-VATE Trial: Efficacy and Safety by Baseline CD22 Expression Level. Kantarjian H. Saturday, December 9. Session Type: Poster Session 5:30 p.m. – 7:30 p.m. EDT. Location: Building A, Level 1, Hall A2.

(Abtract 1328) Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia in Real-World US Practices. LeBlanc T. Saturday, December 9. EDT. Session Type: Poster Session. Presentation Time: 5:30 p.m. – 7:30 p.m. EDT. Location: Building A, Level 1, Hall A2.

(Abtract 2574) Inotuzumab Ozogamicin (InO) Vs Standard of Care (SC) in Patients with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL): Long-Term Results of the Phase 3 INO-VATE Study. Kantarjian H. Sunday, December 10. Session Type: Poster Session. 6:00 p.m. – 8:00 p.m. EDT. Location: Building A, Level 1, Hall A2.

(Abtract 2538) Effect of Renal and/or Hepatic Impairment on the Pharmacokinetics and Safety of Inotuzumab Ozogamicin in Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia. Garrett M. Sunday, December 10. Session Type: Poster Session. 6:00 p.m. – 8:00 p.m. EDT. Location: Building A, Level 1, Hall A2.

(Abtract 2557) Inotuzumab Ozogamicin (InO) for Relapsed/Refractory Acute Lymphoblastic Leukemia (R/R ALL) in the Global Phase 3 INO-VATE Trial: Efficacy by MLL Status. Advani A. Sunday, December 10. Session Type: Poster Session 6:00 p.m. – 8:00 p.m. EDT. Location: Building A, Level 1, Hall A2.
(Abstract 2558) Indirect Treatment Comparison (ITC) of Inotuzumab Ozogamicin (InO) and Blinatumomab (Blina) for Relapsed or Refractory (RR) Acute Lymphoblastic Leukemia (ALL). Stelljes M. Sunday, December 10. Session Type: Poster Session 6:00 p.m. – 8:00 p.m. EDT. Location: Building A, Level 1, Hall A2.

(Abstract N/A) Population Pharmacokinetic/Pharmacodynamic Evaluation of the Effect of Inotuzumab Ozogamicin on QT Intervals in Acute Lymphoblastic Leukemia (ALL) and Non-Hodgkin Lymphoma (NHL) Patients. Hibma J. Session Type: Publication Only.

UCART19:


####